50. Vitrakvi

Cancer in newspaper clipping
(PDPics / Pixabay)

Active ingredient: larotrectinib
Disease: solid tumors with NTRK gene fusion
Peak sales estimate: $850 million
Approved: Nov. 26
Company: Bayer and Loxo Oncology

The scoop: Bayer and Loxo Oncology in November picked up FDA approval for their "tissue agnostic" cancer med Vitrakvi, a costly drug approved to treat tumors featuring a neurotrophic receptor tyrosine kinase gene fusion. Unlike traditional treatment, the first-in-class drug doesn’t target tumors in a particular location but instead attacks cancers throughout the body that feature a specific biomarker. Bayer bought into Loxo's TRK inhibitor programs last year in a deal that featured $400 million up front plus up to more than $1 billion in potential milestone and royalty payments. The drug carries a list price of nearly $400,000, but Bayer unveiled plans to refund payment if patients don't respond within 90 days and to provide reimbursement as well as patient assistance services. Analysts have projected $700 million to $850 million in peak sales. — Eric Sagonowsky

50. Vitrakvi
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.